BioXcel Therapeutics Inc (NASDAQ:BTAI) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totalling 944,000 shares, a growth of 39.9% from the June 15th total of 674,800 shares. Based on an average daily trading volume, of 456,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 9.0% of the company’s stock are sold short.
Shares of BTAI stock opened at $49.98 on Wednesday. The stock’s 50 day simple moving average is $50.34 and its 200 day simple moving average is $30.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.82 and a current ratio of 6.82. BioXcel Therapeutics has a twelve month low of $3.76 and a twelve month high of $61.50. The company has a market capitalization of $970.69 million, a price-to-earnings ratio of -21.27 and a beta of 2.12.
BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.21). On average, analysts forecast that BioXcel Therapeutics will post -2.96 EPS for the current fiscal year.
BTAI has been the topic of several recent analyst reports. Canaccord Genuity reissued a “buy” rating and set a $71.00 price target on shares of BioXcel Therapeutics in a research report on Wednesday, May 13th. BMO Capital Markets raised their price objective on BioXcel Therapeutics from $26.00 to $64.00 in a research report on Tuesday, March 10th. HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of BioXcel Therapeutics in a research report on Monday. Bank of America started coverage on BioXcel Therapeutics in a research report on Wednesday, April 1st. They set a “buy” rating and a $45.00 price objective for the company. Finally, BidaskClub upgraded BioXcel Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 25th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $66.67.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.